Physician profile
Munir S Janmohamed
NPI 1194840694
$314,287.14
in general payments reported to CMS, 2019-2025
26 companies · $80K in 2025
The $80K reported for 2025 was more than what 96% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $16K · 2021: $18K · 2022: $42K · 2023: $44K · 2024: $48K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122K · Travel and Lodging: $24K · Consulting Fee: $15K · Food and Beverage: $12K · Education: $63.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122,018.00 |
| Travel and Lodging | $23,675.53 |
| Consulting Fee | $14,517.50 |
| Food and Beverage | $12,160.37 |
| Education | $63.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $116,205.76 | 2019-2025 | Uptravi, Opsumit |
| Astrazeneca Pharmaceuticals Lp | $36,704.52 | 2020-2025 | Wainua, Farxiga, Brilinta |
| Novartis Pharmaceuticals Corporation | $34,701.57 | 2019-2025 | Entresto |
| Pfizer INC. | $28,473.80 | 2019-2025 | |
| Bridgebio Pharma, INC. | $24,679.68 | 2025 | Attruby |
| Abbott Laboratories | $21,085.79 | 2019-2025 | Amplatzer Talisman, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Bayer Healthcare Pharmaceuticals INC. | $16,361.78 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16,203.97 | 2021-2025 | Jardiance |
| Cvrx, INC. | $6,735.79 | 2023-2025 | Barostim Neo System |
| Lilly USA, LLC | $3,451.24 | 2024-2025 | Jardiance |
| Abiomed | $2,017.22 | 2019-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,319.19 | 2019-2024 | Lifevest |
| Medtronic Vascular, INC. | $1,251.03 | 2019-2020 | |
| Medtronic, INC. | $926.32 | 2024 | Micra |
| United Therapeutics Corporation | $922.80 | 2019-2023 | Tyvaso, Remodulin, Orenitram |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $862.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $773.49 | 2022-2025 | Camzyos |
| Merck Sharp & Dohme LLC | $433.89 | 2023-2025 | Winrevair |
| Alnylam Pharmaceuticals INC. | $263.81 | 2021-2025 | Onpattro, Amvuttra |
| Novo Nordisk INC | $253.40 | 2022-2025 | Wegovy |
| Atricure, INC. | $202.66 | 2023-2024 | |
| Boston Scientific Corporation | $179.52 | 2020-2025 | Watchman Flx |
| Amarin Pharma, INC. | $122.31 | 2023 | |
| Vifor Pharma, INC. | $84.00 | 2019 | |
| Scpharmaceuticals INC. | $55.66 | 2023-2024 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Munir Janmohamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.